FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon

Published: Aug 23, 2012

by Richard Daverman, PhD

August 22, 2012 -- FortuneRock of the US has received SFDA approval to begin China clinical trials of its long-acting formulation of Interferon-a2a. Fortune developed the product using its proprietary fusion technology to create a drug that is administered every 14 days. Existing forms of interferon require patients to receive an injection every day or once per week. FortuneRock operates in China through its wholly owned foreign enterprise company, FortuneRock (China) Ltd. More details....

Back to news